Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ONCR

Oncorus (ONCR) Stock Price, News & Analysis

Oncorus logo

About Oncorus Stock (NASDAQ:ONCR)

Key Stats

Today's Range
$0.13
$0.20
50-Day Range
$0.01
$0.13
52-Week Range
$0.01
$0.47
Volume
135,947 shs
Average Volume
1.33 million shs
Market Capitalization
$3.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company develops ONCR-021 for the treatment of non-small cell lung cancer, renal cell carcinoma, melanoma, and anaplastic thyroid cancer; and ONCR-788 for the treatment of small cell lung cancer, neuroendocrine prostate, and other neuroendocrine cancers. Oncorus, Inc. was incorporated in 2015 and is headquartered in Andover, Massachusetts.

Receive ONCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncorus and its competitors with MarketBeat's FREE daily newsletter.

ONCR Stock News Headlines

RFL Rafael Holdings, Inc.
This Bull Market Indicator called NVDA at $116
Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…
Comera Life Sciences Holdings Inc
Oncorus Inc Ordinary Shares
ONCR Historical Data
See More Headlines

ONCR Stock Analysis - Frequently Asked Questions

Oncorus, Inc. (NASDAQ:ONCR) announced its quarterly earnings data on Monday, May, 22nd. The company reported ($1.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by $0.48.

Oncorus (ONCR) raised $87 million in an IPO on Friday, October 2nd 2020. The company issued 5,800,000 shares at $14.00-$16.00 per share. Jefferies, Evercore ISI and Piper Sandler served as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncorus investors own include Enterprise Products Partners (EPD), Aeglea BioTherapeutics (AGLE), Athenex (ATNX), Cheniere Energy (LNG), Atreca (BCEL), Fiserv (FI) and Brigham Minerals (MNRL).

Company Calendar

Last Earnings
5/22/2023
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ONCR
Fax
N/A
Employees
64
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.33 per share

Miscellaneous

Free Float
21,633,000
Market Cap
$3.29 million
Optionable
Optionable
Beta
3.60
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:ONCR) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners